Veno-Venous Extracorporeal Membrane Oxygenation for Interstitial Lung Disease Essay

Introduction

Veno-venous extracorporeal membrane oxygenation (VV ECMO) is a form of extracorporeal membrane oxygenation (ECMO) used to provide temporary respiratory support to patients with severe lung damage. VV ECMO has been traditionally used for patients with acute respiratory distress syndrome (ARDS). It has also been used for patients with interstitial lung disease (ILD) as a rescue therapy when standard treatment fails to improve oxygenation and ventilation.

Extracorporeal Membrane Oxygenation for Interstitial Lung Disease

Interstitial lung disease comprises a group of disorders that cause interstitial pneumonia and pulmonary fibrosis. The main pathology of the disease is thickening and scarring of the interstitium resulting in impaired gas exchange and hypoxemia. The fibrosis process also affects the normal functioning of the lungs by reducing their expansion capacity and volume.

VV ECMO can be used to provide temporary respiratory support to patients with ILD whose condition could not be managed by conventional treatment. Thus, VV ECMO is indicated for patients with ILD and severe hypoxemia that is resistant to standard treatment. The main indications for VV ECMO in patients with ILD include:

• Severe hypoxemia

• Refractory respiratory failure

• Acute exacerbation of ILD

• Ventilator-induced lung injury

• Reversible ILD or bridge to lung transplantation

• Hypercapnic respiratory failure

• End-stage disease with limited prognosis

VV ECMO can be indicated for patients with ILD and severe hypoxemia that is resistant to standard treatment. Severe hypoxemia is characterized by a decreased partial pressure of oxygen (PaO2) despite a high fraction of inspired oxygen (FiO2). Typical values for PaO2 are less than 60 mm Hg with FiO2 greater than 0.9 or a ratio of PaO2/FiO2 less than 60 mm Hg. In addition, severe hypoxemia can also develop in patients who have been placed on a ventilator due to the inability of VV ECMO to prevent atelectasis and alveolar hypoventilation. The use of VV ECMO in patients with severe hypoxemia helps reduce ventilator-induced lung injury by off-loading the lungs and recruiting alveoli.

VV ECMO can be indicated for patients with ILD and acute exacerbation of ILD. Patients with acute exacerbation of ILD usually require mechanical ventilation due to rapid deterioration of their lung function. In addition, acute exacerbation of ILD can also be resistant to conventional treatment. Thus, VV ECMO can be used to allow the lungs of such patients to heal and return to normal function.

Another indication for the use of VV ECMO in patients with ILD is ventilator-induced lung injury (VILI). VILI is a condition caused by mechanical ventilation that can lead to atelectasis, alveolar collapse, and pulmonary edema. It usually occurs when patients are placed on mechanical ventilation with high pressure support. VILI can be prevented by using VV ECMO to off-load the lungs by reducing alveolar pressure.

In addition, VV ECMO can also be used as a bridge to lung transplantation for patients with end-stage ILD. Thus, VV ECMO can be used in patients with ILD who need a lung transplant, but a suitable donor is unavailable. Apart from being a bridge to lung transplantation, VV ECMO can also be indicated for the management of hypercapnic respiratory failure.

How VV ECMO Works for Interstitial Lung Disease

VV ECMO works in a similar way for patients with ILD and patients with ARDS. The main indication for the use of VV ECMO for patients with ILD is to provide respiratory support for patients with severe hypoxemia. The main difference between VV ECMO for patients with ILD and patients with ARDS is that ILD affects the lung tissues resulting in fibrosis while ARDS affects the alveoli.

VV ECMO involves the cannulation of a large vein, such as the femoral or internal jugular vein, and connecting it to an oxygenator. The oxygenator adds oxygen to the blood and removes carbon dioxide. The oxygenated blood is then pumped back into the venous system, from where it is distributed to the rest of the body. Patients who undergo VV ECMO usually require mechanical ventilation to aid in the gas exchange process. The pressure of the ventilator can be reduced to reduce lung injury.

The VV ECMO circuit usually requires frequent monitoring to ensure that it is working correctly and to avoid complications, such as coagulation and embolism. In addition, patients who undergo VV ECMO usually require frequent laboratory tests and monitoring of their vital signs.

Benefits of VV ECMO for Patients With Interstitial Lung Disease
VV ECMO provides respiratory support to patients with ILD thus allowing their lungs to heal and reducing ventilator-induced lung injury. Some of the benefits of using VV ECMO for patients with ILD include:

Reduction of ventilator-induced lung injury in patients with ILD

VV ECMO reduces ventilator-induced lung injury by off-loading the lungs. The risk of ventilator-induced lung injury is high in patients with ILD due to the fragile nature of their lungs.

Lung rest
VV ECMO allows the lungs to rest and heal. The benefit of lung rest is significant in patients with ILD due to the reduced lung capacity resulting from the loss of lung tissue.

Bridge to recovery
VV ECMO can be used as a bridge to recovery for patients with acute exacerbation of ILD. Thus, it can help the lungs of patients with acute exacerbation of ILD to heal.

Bridge to lung transplant
In addition to being a bridge to recovery, VV ECMO can also be used as a bridge to lung transplant for patients with end-stage ILD.

Improvement in oxygenation and removal of carbon dioxide
VV ECMO improves oxygenation and facilitates the removal of carbon dioxide from the body thus reducing the risk of hypercapnia.

Potential for treatment of refractory ARDS
VV ECMO can also be used to manage patients with ILD that is complicated by refractory ARDS.

Risks and Challenges of Using VV ECMO in Patients With Interstitial Lung Disease
The use of VV ECMO in patients with ILD is usually associated with a number of risks and challenges, including:

Bleeding
Patients who undergo VV ECMO usually require anticoagulation to prevent the formation of clots in the ECMO circuit. Thus, patients who undergo VV ECMO are at risk of developing life-threatening bleeding, such as intracranial hemorrhage, gastrointestinal hemorrhage, and bleeding at the cannula sites. Patients with ILD are also at greater risk of developing bleeding due to the use of corticosteroids.

The risk of infection is particularly high among critically ill patients who undergo VV ECMO.

Vascular injury
The risk of vascular injury is high among patients who undergo VV ECMO due to the need to place cannulas in large veins. Vascular injuries that may occur include limb ischemia and deep vein thrombosis.

Organ failure
The use of VV ECMO is usually associated with the development of multiple organ failure, particularly in critically ill patients.

Complications related to the ECMO circuit
VV ECMO requires constant monitoring to detect complications related to the ECMO circuit, such as inappropriate blood flow, oxygenator membrane rupture, and pump failure. In addition, due to the need for anticoagulation, there is a high risk of clotting of the ECMO circuit.

Limited duration of use
ECMO is mainly used as a short-term therapy. Thus, patients who undergo VV ECMO will need to be weaned off the machine after their respiratory function has been restored.

Outlook
The outlook for patients who undergo VV ECMO for ILD mainly depends on the cause and severity of the disease, as well as the timing of the intervention. Patients with acute exacerbation of ILD who respond well to VV ECMO can be discharged on the same day as the intervention. However, most patients who undergo VV ECMO for ILD require hospitalization for several days or weeks. Patients who develop ILD following viral infections have a better prognosis than patients who develop ILD from other causes.

Conclusion
VV ECMO can provide significant respiratory support to patients with severe ILD who do not respond to conventional treatment. It can also be used as a bridge to lung transplantation for patients with end-stage ILD. VV ECMO can significantly improve the respiratory function of patients with acute exacerbation of ILD. However, it is a highly invasive procedure that is associated with a number of risks and limitations. Thus, it should be reserved for patients with acute exacerbation of ILD who do not respond to standard treatment.